IJCS | Volume 32, Nº1, January/ February 2019

59 1. Murcia L, Carrilero B, Fau - Saura D, Iborra MA, Segovia M. Diagnosis and treatment of Chagas disease. Enferm Infec Mirobiol Clin. 2013;31(Suppl 1):26-34. 2. Carvalho G, Rassi S, Bastos JMDA, Câmara SSP. Coronariopatia assintomática em chagásicos com insuficiência cardíaca: prevalência e fatores de risco. Arq Bras Cardiol. 2011; 97(5):408-12. 3. Nogueira PR, Rassi S, Corrêa KS. Perfil epidemiológico, clínico e terapêutico da insuficiência cardíaca em hospital terciário. Arq Bras Cardiol. 2010;95(3)392-8. 4. Silva SJ, Rassi S, Silva C. Ausência de associação do polimorfismo dos alelos D/I do gene da enzima conversora de angiotensina (ECA) em pacientes com insuficiência cardíaca. Rev Bras Med. 2015,72(4):130-5. 5. Carvalho APPF, Rassi S, Fontana KE, Correa KS, Feitosa RHF. Influência da suplementação de creatina na capacidade funcional de pacientes com Insuficiência Cardíaca. Arq Bras Cardiol. 2012,99(1):623-9. 6. Skrzynia C, Berg JS, Willis MS, Jensen BC. Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev. 2015;11(1):10-7. 7. Hamad E, Feldman AM. Pharmacogenetics in heart failure: how it will shape the future. Heart Fail Clin. 2010,6(1):1-10. 8. Bocchi EA, Braga FGM, Ferreira SMA, Rohde LEP, OliveiraWA, Almeida DR et al., Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insuficiência cardíaca crônica. Arq Bras Cardiol. 2009;93(1 Suppl 1):1-71. 9. CuocoMAR, PereiraAC,MotaGFA, Krieger JE,Mansur AJ. Polimorfismo genético, terapia farmacológica e função cardíaca sequencial empacientes com insuficiência cardíaca. Arq Bras Cardiol. 2008;90(4):274-9. 10. Covolo L, Gelatti U, Metra M, Donato F, Nodari S, Pezzali N, et al. Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. Biomarkers. 2003;8(5):429-36. 11. de Groote P, HelbecqueN, LamblinN, Hermant X, Amouyel P, Bauters C, et al. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail. 2004;6(1):17-21. 12. Schut AF, Bleumink GS, Stricker BH, Hofman A, Witteman JC, Pols HA, et al. Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J. 2004;25(23):2143-8. 13. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between angiotensin- converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44(10):2019-26. 14. Genetics Home Reference. Chromossome 17 [Cited in 2018 Jun 12]. Available from: https://ghr.nlm.nih.gov/chromosome/17 15. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018. American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr. 2018;31(3):241-74. 16. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F et al. A prospective evaluation of an angiotensin-converting- enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332(11):706-11. 17. Margoto G, Colombo RCR, Gallani MCBJ. Características clínicas e psicossociais do paciente com insuficiência cardíaca que interna por descompensação clínica. Rev Esc Enferm USP. 2009;43(1):44-53. 18. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990- 1994. Circulation. 2006;113(6):799-805. References Silva et al. ACE polymorphism and echocardiographic data in HF Int J Cardiovasc Sci. 2019;32(1)55-60 Original Article Conclusions This study suggests that ACE (D/I) polymorphism is not related with echocardiographic parameters of patients with HF caused by Chagas disease. Further larger, prospective studies are needed to determinewhich factorsmay be associatedwithHF caused by Chagas disease and investigate the best intervention with minimal adverse effects in this population. Author contributions Conception and design of the research: Silva SJ, Rassi S. Acquisition of data: Silva SJ. Analysis and interpretation of the data: Silva SJ, Rassi S, Pereira AC. Statistical analysis: Silva SJ. Obtaining financing: Pereira AC. Writing of the manuscript: Silva SJ. Critical revision of the manuscript for intellectual content: Rassi S, Pereira AC. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This article is part of the thesis of Doctoral submitted by Silene Jacinto da Silva, fromUniversidade Federal de Goiás ( Programa de Pós-graduação em Ciências da Saúde ). Ethics approval and consent to participate This study was approved by the Ethics Committee of the Hospital das Clínicas (UFG) under the protocol number 908.870. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.